WARREN, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, has announced financial results for the fiscal quarter ending September 30, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- St. Charles Residents Urged to Fortify Fencing Against Severe Weather with Fence and Deck Depot’s Expert Guidance - April 18, 2025
- Machine Learning Engineer Interview Course 2025 – Interview Kickstart Releases ML Engineer Course With Interview Prep - April 18, 2025
- Pixelle Specialty Solutions Pauses Chillicothe Mill Closure - April 18, 2025
